Multi-Institutional Analysis of Pancreaticoduodenectomy for Nonfamilial Periampullary Adenoma: A Novel Risk Score to Guide Shared Decision-Making

医学 普通外科 壶腹周围癌 胃肠病学 内科学 胰十二指肠切除术 胰腺
作者
Parit T. Mavani,Caitlin Sok,Nina L. Eng,Angelo Alessandro Marra,Laleh Foroutani,Adnan Alseidi,Hussein M. Hariri,Gregory C. Wilson,Syed A. Ahmad,Charles R. Scoggins,Caitlin A. Hester,Jashodeep Datta,Nipun B. Merchant,Michael T. LeCompte,Han Jo Kim,Gregory Sigler,Nabeel Zafar,Sharon M. Weber,Orjola Prela,Darren R. Carpizo
出处
期刊:Journal of The American College of Surgeons [Lippincott Williams & Wilkins]
卷期号:240 (4): 392-402 被引量:1
标识
DOI:10.1097/xcs.0000000000001289
摘要

BACKGROUND: Pancreaticoduodenectomy (PD) may occasionally be indicated for complete removal of periampullary (duodenal and ampullary) adenomas (PAs). As compared with malignant indications, PD for benign or premalignant disease is often associated with increased morbidity. Although the Spigelman classification assesses malignancy risk for familial adenomatous polyposis (FAP)-related duodenal adenomas, no malignancy risk score (MRS) exists for non-FAP-related PAs. We developed an MRS for non-FAP-related PAs undergoing PD to weigh the risk of malignancy and postoperative morbidity. STUDY DESIGN: We retrospectively analyzed patients with non-FAP-related PA who underwent PD at 8 institutions (2010 to 2022). Patient and lesion factors associated with final malignant pathology were identified using multivariable logistic regression to create MRS. Postoperative complications were assessed according to MRS. RESULTS: Of 127 patients, 59 (46.5%) had evidence of malignancy on final pathology. The odds of malignancy were higher in patients aged 65 years or older (odds ratio [OR] 3.2, p = 0.01), having bile duct 9 mm or more (OR 3.3, p = 0.009), having preoperative symptoms (OR 7.7, p = 0.002), and having high-grade dysplasia (OR 7.5, p < 0.001). A MRS was derived ranging from 0 to 6: age 65 years or older = 1, bile duct 9 mm or more = 1, symptomatic = 2, and high-grade dysplasia = 2. Patients were stratified into low-risk (MRS 1 to 2, n = 26), intermediate-risk (MRS 3 to 4, n = 59), and high-risk groups (MRS 5 to 6, n = 26), with malignancy rates increasing with MRS (10.3%, 44.1%, and 88.2%, p < 0.001). Patients in the no- or low-risk group (MRS 0 to 2) had higher odds of major postoperative complications compared with patients in the intermediate- or high-risk group (MRS 3 or higher, OR 2.9, p = 0.047). CONCLUSIONS: This novel MRS stratifies the risk of malignancy in non-FAP-related PAs managed with PD. This score can be used to counsel patients who may require PD for complete tumor removal about their risk of harboring malignancy and their risk of major postoperative complications.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
蓝天的应助被HUYAOWEI采纳,获得10
刚刚
李健的应助被原料药研发粗人采纳,获得10
1秒前
GIN的应助被zzk采纳,获得10
2秒前
尘南浔发布了新的文献求助10
2秒前
2秒前
ljz668发布了新的文献求助10
3秒前
我在高维宇宙完成签到,获得积分10
3秒前
小马甲的应助被科研通管家采纳,获得10
3秒前
Hello的应助被科研通管家采纳,获得30
3秒前
3秒前
3秒前
Owen的应助被科研通管家采纳,获得10
3秒前
Nole的应助被科研通管家采纳,获得10
3秒前
3秒前
烟花的应助被科研通管家采纳,获得30
3秒前
JamesPei的应助被科研通管家采纳,获得10
4秒前
Jasper的应助被嘿撒采纳,获得10
4秒前
8R60d8的应助被科研通管家采纳,获得10
4秒前
4秒前
打打的应助被科研通管家采纳,获得10
4秒前
4秒前
8R60d8的应助被科研通管家采纳,获得10
4秒前
3089ggf完成签到,获得积分10
4秒前
慕青的应助被科研通管家采纳,获得10
4秒前
4秒前
英姑的应助被科研通管家采纳,获得50
4秒前
桐桐的应助被科研通管家采纳,获得10
4秒前
5秒前
李健的应助被科研通管家采纳,获得10
5秒前
Lucas的应助被科研通管家采纳,获得10
5秒前
JamesPei的应助被科研通管家采纳,获得10
5秒前
研友_VZG7GZ的应助被科研通管家采纳,获得10
5秒前
江二毛发布了新的文献求助10
5秒前
molihuakai的应助被科研通管家采纳,获得10
5秒前
HUYAOWEI完成签到,获得积分10
5秒前
5秒前
丘比特的应助被科研通管家采纳,获得10
5秒前
领导范儿的应助被科研通管家采纳,获得10
5秒前
野性的骁完成签到,获得积分10
6秒前
Ava的应助被科研通管家采纳,获得10
6秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8193361
求助须知:如何正确求助?哪些是违规求助? 9579602
关于积分的说明 21866201
捐赠科研通 7792983
什么是DOI,文献DOI怎么找? 3437263
关于科研通互助平台的介绍 2560718
邀请新用户注册赠送积分活动 2484082